Mahsa Boroon

Efficacy and tolerability of ketamine in moderate to severe obsessive-compulsive disorder: a systematic review.

Psychopharmacology August 27, 2026 Shayan Eghdami, Mahsa Boroon, Amir-Abbas Keshavarz-Akhlaghi et al.

Approximately 40-60% of patients with obsessive-compulsive disorder (OCD) fail to respond to standard serotonergic and behavioral therapies. This systematic review evaluates the efficacy, durability, and safety of ketamine, a glutamate modulator, for moderate to severe OCD. Following PRISMA guidelines, we searched electronic databases through January 2026 for studies treating moderate-to-severe...